BioLineRx Ltd. (BLRX): Price and Financial Metrics

BioLineRx Ltd. (BLRX): $0.63

0.00 (-0.03%)

POWR Rating

Component Grades













Add BLRX to Watchlist
Sign Up

Industry: Biotech



in industry

BLRX Stock Price Chart Interactive Chart >

Price chart for BLRX

BLRX Price/Volume Stats

Current price $0.63 52-week high $1.98
Prev. close $0.63 52-week low $0.55
Day low $0.60 Volume 271,198
Day high $0.63 Avg. volume 269,835
50-day MA $0.66 Dividend yield N/A
200-day MA $1.11 Market Cap 38.76M

BioLineRx Ltd. (BLRX) Company Bio

BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company was founded in 2003 and is based in Modi’in, Israel.

BLRX Latest News Stream

Event/Time News Detail
Loading, please wait...

BLRX Latest Social Stream

Loading social stream, please wait...

View Full BLRX Social Stream

Latest BLRX News From Around the Web

Below are the latest news stories about BIOLINERX LTD that investors may wish to consider to help them evaluate BLRX as an investment opportunity.

BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer. Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions. Her appointment is effective today, January 4, 2023.

Yahoo | January 4, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tueday

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | December 20, 2022

BioLineRx Highlights Early-Stage Trial Data From Cancer Vaccine Candidate

BioLineRx Ltd (NASDAQ: BLRX) announced results from the Phase 1/2a study of the intratumoral cancer vaccine candidate AGI-134 in patients with unresectable metastatic solid tumors. The study met its primary endpoint of AGI-134's safety and tolerability. In this first-in-human trial, 38 patients were treated with AGI-134. Part 1 demonstrated that AGI-134 was safe and well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached, and the recommended dose for

Yahoo | December 20, 2022

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from the Phase 1/2a study of intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.

Yahoo | December 20, 2022

BLRX: Self-Commercialization in the US

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT Third Quarter 2022 Operational and Financial Results On November 15, 2022, BioLineRx Ltd. (NASDAQ:BLRX) reported 3Q:22 operational and financial results in a press release concurrent with the filing of Form 6-K . A conference call and webcast were hosted later that morning. Key highlights since the previous earnings update

Yahoo | December 5, 2022

Read More 'BLRX' Stories Here

BLRX Price Returns

1-mo 6.78%
3-mo -26.74%
6-mo -60.37%
1-year -65.38%
3-year -73.31%
5-year -96.07%
YTD 6.78%
2022 -71.08%
2021 -19.05%
2020 12.00%
2019 -65.91%
2018 -59.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6308 seconds.